Sinclair Range Inc. is pleased to introduce a compelling equity and/or strategic partnership opportunity in Sirona Pharma Inc. (“Sirona” or the “Company”), a Health Canada-licensed premium cannabis producer currently navigating a structured exit from creditor protection under the Companies’ Creditors Arrangement Act (“CCAA”). This financing will facilitate the Company’s exit from CCAA and position it to capitalize on significant near-term revenue opportunities in both domestic medical and international premium markets.

Sirona operates a state-of-the-art, 130,000 square foot indoor cultivation and processing facility near Peers, Alberta and holds significant hard assets, including land and buildings appraised at C$47 million (June 2024) and equipment with a cost value in excess of C$12 million. The Company is well positioned to exit its current restructuring in the coming months, with its Health Canada cultivation licence expected to be reinstated in March 2026. We are seeking a strategic partner or equity investor to provide C$6.0 million in capital to facilitate this exit and position the business for accelerated growth.

The Opportunity at a Glance

Sirona Pharma has operated its purpose-built indoor facility since 2014. The Company was founded by Jean Chiasson, a master grower with decades of experience developing proprietary genetic strains, and Dr. J. Gupta, a practicing medical doctor and cannabis researcher. Together, they have spent their careers developing genetics and treatment protocols specifically tailored to medical-grade cannabis applications. Both founders have returned to active leadership roles — Mr. Chiasson as Master Grower and Dr. Gupta as Chief Medical Officer — bringing renewed strategic focus and operational depth to the business.

The facility is equipped with 2,800 light capacity across four phases, dedicated processing space for extracts, vapes and pre-rolls, and fully operational e-commerce order fulfilment infrastructure. Phase 3 alone – comprising 22 rooms and 1,100 lights – is capable of producing approximately 10,000 kilograms of premium dried flower annually. The Company exited the domestic recreational market in January 2025 and has strategically repositioned toward higher-margin medical and international premium markets, where its proprietary genetics and indoor growing environment command significant pricing premiums.

Investment Highlights

  • Significant hard asset coverage: appraised real property of C$47M and equipment at C$12M cost value substantially underpin the investment.
  • Licence reinstatement imminent: Health Canada cultivation licence expected to be reinstated in March 2026, unlocking immediate production and revenue.
  • Proven facility with operational infrastructure: purpose-built, modern indoor growing environment with processing and e-commerce fulfilment capabilities already in place.
  • Proprietary genetics and founding expertise: Mr. Chiasson’s exclusive genetic strains and cultivation methodology are optimized for the ultra-premium and medical-grade product specifications demanded by international wholesale buyers.
  • Strong near-term demand: international wholesale buyers are actively seeking ultra-premium and exotic product; the Company has established channels capable of absorbing substantially all production output at premium pricing.
  • Medical market growth: Dr. Gupta is leading the development of a direct-to-patient medical distribution channel, with e-commerce infrastructure already deployed.
  • Clear path to profitability: financial projections indicate EBITDA-positive operations commencing in the second half of 2026, scaling to C$26M+ cumulative EBITDA over the forecast period.
  • Restructuring oversight: Sinclair Range Inc. is acting as Chief Restructuring Officer, providing operational management support and financial discipline throughout the CCAA process and exit.

Use of Proceeds

The C$6.0 million will be deployed as follows:

  • Retirement of the existing Debtor-in-Possession (DIP) facility, facilitating a clean exit from CCAA proceedings.
  • Restoration of full Health Canada regulatory compliance and recommencement of cultivation operations.
  • Working capital to fund the initial production ramp, fulfilment of international wholesale orders, and launch of the medical e-commerce distribution channel.

Next Steps

If this opportunity aligns with your investment thesis or strategic objectives, we would welcome a conversation. Please reach out directly to:

Scott Sinclair

President, Sinclair Range Inc.

Mobile: 646 670 0800

Email: ssinclair@sinclairrange.com